No One-Size-Fits-All Solution for Autologous Cell Therapy Manufacturing

Autologous cell therapy manufacturing presents unique operational challenges, according to researchers. Choosing a suitable manufacturing model is crucial to address the specific logistical and economic hurdles, says Zhaowei Li, a researcher at the Georgia Institute of Technology. Each patient in an autologous therapy represents an individual batch, requiring careful handling of patient-specific starting material, a chain of identity, and precise coordination of collection, manufacturing, release, and return.

Researchers explored three potential models: centralized production, a coordinated point-of-care (POC) network, and an independent network. A coordinated POC network, where sites share real-time information on patient specimens, reagent inventory, and manufacturing capacity, can provide a balance between cost and turnaround time, according to Li. In their study, coordinated POC manufacturing remained within 1.2% of the centralized system's cost while reducing average turnaround time from 29.5 to 28.2 days.

However, Li notes that coordinated POC may not be ideal when demand is low or geographically concentrated, or when centralized transportation is reliable and inexpensive. In such cases, centralized production could be a more cost-effective option. Independent POC manufacturing, while slightly faster (27.5 days), is approximately 43.5% more expensive than the coordinated POC model.

The researchers emphasize that their findings should be seen as decision support under specific assumptions, rather than a one-size-fits-all solution.